{"brief_title": "An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF", "brief_summary": "Open-label therapy will be administered to up to 220 patients, following completion of either InterMune Protocol GIPF-002 Part B or Protocol GIPF-004, to assess the long-term safety of subcutaneous Interferon gamma-1b. The study duration will be 5 years.", "detailed_description": "Open-label therapy will be administered subcutaneously. Patients enrolled will continue to receive Interferon gamma-1b therapy three times per week and will be evaluated at 6-week intervals. Patients not taking Interferon gamma-1b at enrollment will re-initiate therapy with subcutaneous Interferon gamma-1b under a dose-escalation scheme, reaching full dose after 2 weeks.", "condition": ["Idiopathic Pulmonary Fibrosis", "Pulmonary Fibrosis", "Lung Disease"], "intervention_type": ["Drug"], "intervention_name": ["Interferon gamma-1b"], "description": ["200 mcg, SQ, 3x per week"], "criteria": "Inclusion criteria: - Enrollment in Protocol GIPF 002 Part B or GIPF-004 - Completion of the End of Treatment Visit in Protocol GIPF-002 Part B or the Study Completion Visit in GIPF-004 - Able to understand and sign a written informed consent form and comply with the requirements of the study Exclusion criteria: - pregnancy or lactation - lack of adherence to either GIPF-002 or GIPF-004 study protocols and treatment regimens - if Principal Investigator deems patient is unsuitable for study", "gender": "All", "minimum_age": "N/A", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "InterMune", "mesh_term": ["Fibrosis", "Lung Diseases", "Pulmonary Fibrosis", "Idiopathic Pulmonary Fibrosis", "Idiopathic Interstitial Pneumonias", "Interferons", "Interferon-gamma"], "id": "NCT00076635"}